The field of psychedelic research has been gaining traction, with significant interest in substances like MDMA and psilocybin for their therapeutic potential. Recently, however, the FDA advisory panel recommended against the approval of MDMA-assisted psychotherapy for PTSD, citing that the risks outweigh the benefits. This decision has stirred debate within the psychedelic community about the inherent challenges and varying approaches in psychedelic-assisted therapy.

The FDA advisory committee expressed........

© Psychology Today